Incyte’s Minjuvi (Tafasitamab) Combination Gains the MHLW Approval for R/R DLBCL

Shots: The MHLW has approved Minjuvi (tafasitamab) + Lenalidomide for the treatment of adult pts. with r/r diffuse large B-cell lymphoma (DLBCL) Approval was based on the international P-II (L-MIND) trial, & a Japanese P-Ib/II (J-MIND) trial (Group 6) assessing Minjuvi + lenalidomide in pts with r/r DLBCL who are not eligible for autologous stem…

ByRidhi RastogiJune 19, 2026

NEWS

Genentech Reports the US FDA’s sBLA Acceptance of Lunsumio VELO + Polivy for R/R Large B-Cell Lymphoma

Shots: The US FDA has accepted sBLA for Genentech's Lunsumio VELO (mosunetuzumab-axgb; SC) + Polivy (polatuzumab vedotin-piiq) for treating adults with r/r LBCL, incl. diffuse large B-cell lymphoma (DLBCL), after ≥1L of systemic therapy (PDUFA: Feb 9, 2027) sBLA was backed by the P-III (SUNMO) study assessing Lunsumio VELO + Polivy (IV) vs R-GemOx in the above…

ByRidhi RastogiJune 18, 2026

NEWS

HUTCHMED Initiates P-III Trial of HMPL-760 + R-GemOx for R/R Diffuse Large B-cell Lymphoma in China

Shots: HUTCHMED has initiated a P-III trial of HMPL-760 + R-GemOx (rituximab, gemcitabine and oxaliplatin) in r/r DLBCL Chinese pts, with first patient dosing achieved on Mar 20, 2026 Trial will evaluate efficacy, safety, & PK of HMPL-760 vs PBO, both in combination with R-GemOx in r/r DLBCL pts (n=~240) who are who are relapsed or…

ByRidhi RastogiMarch 23, 2026

NEWS

AbbVie Reports Topline P-III (EPCORE DLBCL-1) Trial Data on Epcoritamab for R/R Diffuse Large B-cell Lymphoma (DLBCL)

Shots: AbbVie has reported topline P-III (EPCORE DLBCL-1) trial results assessing epcoritamab vs chemoimmunotherapy (R-GemOx or BR) in 483 adults with r/r DLBCL, who had received ≥1L of therapy (73% had received ≥2L) & were ineligible for HDT-ASCT Trial showed improved PFS, with improvements across CRR, DoR, & time to next treatment, plus the study did not…

ByRidhi RastogiJanuary 19, 2026

NEWS

Incyte Reports the Topline P-III (frontMIND) Trial Data on Monjuvi (Tafasitamab) Combination for Diffuse Large B-Cell Lymphoma

Shots: The P-III (frontMIND) trial assessed Monjuvi (Minjuvi in EU) + lenalidomide & R-CHOP vs R-CHOP as the 1L treatment in ~900 adults with previously untreated DLBCL (IPI score of 3-5 for pts >60yrs or aaIPI of 2-3 for pts ≤60yrs.) Trial met its 1EP of improved PFS by investigator assessment & achieved its key…

ByRidhi RastogiJanuary 6, 2026

VIEWPOINTS

Patient Characteristics Trends in CAR-T Therapies: Dr. Ira Zackon in a Stimulating Discussion with PharmaShots

Shots: In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression PharmaShots welcomes Dr. Ira Zackon,…

BySaurabh ChaubeyJune 18, 2025

VIEWPOINTS

Standardizing DLBCL Treatment: Dr. John Burke in a Riveting Conversation with PharmaShots

Shots: In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…

BySaurabh ChaubeyJune 16, 2025

NEWS

Genentech Reports P-III (STARGLO) Trial Data on Columvi for R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Shots: Genentech has reported 2yr. P-III (STARGLO) trial data assessing Columvi + GemOx vs Rituxan + GemOx in previously treated ASCT-ineligible r/r DLBCL pts At 24.7mos. mFU, trial showed a 40% improvement in OS (mOS: not reached vs 13.5mos.), a 59% reduction in risk of progression or death, & CRs in 58.5% vs 25.3% pts;…

ByRidhi RastogiMay 26, 2025

NEWS

China’s NMPA Grants Approval to InnoCare Pharma’s Minjuvi + Lenalidomide to Treat R/R DLBCL

Shots: InnoCare Pharma has approved Minjuvi (tafasitamab) + Lenalidomide, followed by Minjuvi monotx., for treating adult pts. with r/r diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT) Tafasitamab, a humanized Fc-modified cytolytic CD19-targeting immunotherapy, combined with lenalidomide, is already approved for treating eligible DLBCL pts. in Hong Kong, Macau,…

ByDipanshu DixitMay 21, 2025

NEWS

Roche’s Columvi (Glofitamab) Regimen Receives the EC’s Approval to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Shots: The EC has granted full approval to Columvi + GemOx for ASCT-ineligible r/r DLBCL pts based on P-III (STARGLO) trial assessing the regimen vs MabThera/Rituxan + GemOx in previously treated DLBCL pts At 11.3mos. mFU (primary analysis), trial showed improved OS, a 41% reduction in death risk, with a 63% improvement in PFS. At…

ByRidhi RastogiApril 14, 2025

Incyte’s Minjuvi (Tafasitamab) Combination Gains the MHLW Approval for R/R DLBCL

Genentech Reports the US FDA’s sBLA Acceptance of Lunsumio VELO + Polivy for R/R Large B-Cell Lymphoma

HUTCHMED Initiates P-III Trial of HMPL-760 + R-GemOx for R/R Diffuse Large B-cell Lymphoma in China

AbbVie Reports Topline P-III (EPCORE DLBCL-1) Trial Data on Epcoritamab for R/R Diffuse Large B-cell Lymphoma (DLBCL)

Incyte Reports the Topline P-III (frontMIND) Trial Data on Monjuvi (Tafasitamab) Combination for Diffuse Large B-Cell Lymphoma

Patient Characteristics Trends in CAR-T Therapies: Dr. Ira Zackon in a Stimulating Discussion with PharmaShots

Standardizing DLBCL Treatment: Dr. John Burke in a Riveting Conversation with PharmaShots

Genentech Reports P-III (STARGLO) Trial Data on Columvi for R/R Diffuse Large B-Cell Lymphoma (DLBCL)

China’s NMPA Grants Approval to InnoCare Pharma’s Minjuvi + Lenalidomide to Treat R/R DLBCL

Roche’s Columvi (Glofitamab) Regimen Receives the EC’s Approval to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Contact US

FOLLOW US